ArticleDiabetes care2026
White Matter Hyperintensities Moderate the Association Between Diabetes and Non-AD Brain Atrophy.
Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cognitive Function Mediates the Association Between Type 2 Diabetes and Physical Performance Decline in Older Adults: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Discrete White Matter Lesions in Clusters and Harmony: Using Oblique Strategies to Study Brain Aging.Diabetes care · 2026Article
- Type 2 Diabetes and the Lung - Cause and Consequence.Current diabetes reports · 2026Review
- Free water-mediated associations among choroid plexus enlargement, white matter lesions, and cognitive performance in type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
objectiveWhite matter hyperintensities (WMHs) moderate the association between diabetes and cognition, but the underlying mechanisms remain unknown. This study investigated the interaction effect between diabetes and WMHs on brain atrophy, the resulting atrophy patterns, and whether brain atrophy mediates the effect of diabetes on cognition. RESEARCH DESIGN AND
methodsThis study included individuals without dementia from two independent memory clinic-based cohorts: Harmonization (primary analysis, n = 112 case subjects with diabetes, n = 284 control subjects) and Alzheimer's Disease Neuroimaging Initiative (ADNI) (secondary analysis, n = 64 case subjects with diabetes, n = 600 control subjects). Participants underwent longitudinal brain MRI and cognitive assessments, along with plasma pTau181 measurement as a marker of Alzheimer disease (AD). WMHs and brain atrophy were quantified, with Schwarz signature, McEvoy signature, and hippocampal volume used as AD-specific atrophy measures.
resultsDiabetes was not associated with brain atrophy cross-sectionally or longitudinally. Instead, an interactive effect between diabetes and WMHs on brain atrophy was observed. In Harmonization, this interaction was significant in cross-sectional analyses, affecting cortical gray matter and the frontal lobe. No interactive effect was found for AD-specific atrophy, and the observed interactive effect remained significant after adjusting for plasma pTau181. Cortical gray matter mediated the effect of diabetes on cognition at higher WMHs burden. These results were replicated in ADNI, where diabetes and WMHs interacted to accelerate brain atrophy over time.
conclusionsOur study demonstrated diabetes and WMHs synergistically contribute to brain atrophy independent of AD, suggesting diabetes-associated cognitive impairment is primarily driven by cerebrovascular disease rather than Alzheimer pathology.
Indexed as
Identifiers
41144252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.